Do Kim
Stock Analyst at Piper Sandler
(2.04)
# 2,945
Out of 4,896 analysts
92
Total ratings
44.93%
Success rate
3.01%
Average return
Main Sectors:
Stocks Rated by Do Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $62 → $63 | $41.73 | +50.97% | 18 | Feb 22, 2024 | |
| TVTX Travere Therapeutics | Maintains: Overweight | $42 → $46 | $16.46 | +179.47% | 6 | Feb 21, 2023 | |
| VRTX Vertex Pharmaceuticals | Maintains: Neutral | $296 | $468.85 | -36.87% | 13 | Feb 8, 2023 | |
| GILD Gilead Sciences | Maintains: Overweight | $111 → $112 | $109.64 | +2.15% | 7 | Feb 3, 2023 | |
| SDGR Schrödinger | Maintains: Overweight | $86 → $87 | $21.01 | +314.09% | 5 | Jan 19, 2023 | |
| CDXS Codexis | Maintains: Overweight | $22 → $23 | $2.99 | +669.23% | 2 | Jan 19, 2023 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $10 → $20 | $18.88 | +5.93% | 3 | Aug 17, 2022 | |
| REPL Replimune Group | Maintains: Overweight | $44 → $43 | $10.97 | +291.98% | 2 | Aug 16, 2022 | |
| EXEL Exelixis | Maintains: Overweight | $30 → $32 | $44.86 | -28.67% | 1 | Jul 26, 2022 | |
| ABCL AbCellera Biologics | Maintains: Overweight | $21 → $22 | $4.01 | +448.63% | 4 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $19 | $37.44 | -49.25% | 3 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $2.20 | +627.27% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $185 | $314.94 | -41.26% | 14 | Jan 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $7.27 | +12,279.64% | 1 | Dec 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $35 | $57.15 | -38.76% | 11 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $20 | $1.15 | +1,639.13% | 1 | Mar 6, 2018 |
Ionis Pharmaceuticals
Feb 22, 2024
Maintains: Overweight
Price Target: $62 → $63
Current: $41.73
Upside: +50.97%
Travere Therapeutics
Feb 21, 2023
Maintains: Overweight
Price Target: $42 → $46
Current: $16.46
Upside: +179.47%
Vertex Pharmaceuticals
Feb 8, 2023
Maintains: Neutral
Price Target: $296
Current: $468.85
Upside: -36.87%
Gilead Sciences
Feb 3, 2023
Maintains: Overweight
Price Target: $111 → $112
Current: $109.64
Upside: +2.15%
Schrödinger
Jan 19, 2023
Maintains: Overweight
Price Target: $86 → $87
Current: $21.01
Upside: +314.09%
Codexis
Jan 19, 2023
Maintains: Overweight
Price Target: $22 → $23
Current: $2.99
Upside: +669.23%
Rigel Pharmaceuticals
Aug 17, 2022
Maintains: Neutral
Price Target: $10 → $20
Current: $18.88
Upside: +5.93%
Replimune Group
Aug 16, 2022
Maintains: Overweight
Price Target: $44 → $43
Current: $10.97
Upside: +291.98%
Exelixis
Jul 26, 2022
Maintains: Overweight
Price Target: $30 → $32
Current: $44.86
Upside: -28.67%
AbCellera Biologics
Jul 26, 2022
Maintains: Overweight
Price Target: $21 → $22
Current: $4.01
Upside: +448.63%
Jun 23, 2022
Maintains: Overweight
Price Target: $28 → $19
Current: $37.44
Upside: -49.25%
Mar 8, 2021
Initiates: Outperform
Price Target: $16
Current: $2.20
Upside: +627.27%
Jan 25, 2021
Downgrades: Market Perform
Price Target: $185
Current: $314.94
Upside: -41.26%
Dec 18, 2020
Initiates: Outperform
Price Target: $900
Current: $7.27
Upside: +12,279.64%
May 12, 2020
Maintains: Outperform
Price Target: $27 → $35
Current: $57.15
Upside: -38.76%
Mar 6, 2018
Maintains: Outperform
Price Target: $7 → $20
Current: $1.15
Upside: +1,639.13%